Abstract:BACKGROUND:Blockade of angiotensin II type 1 (AT1) receptors ameliorates brain inflammation, and reduces excessive brain interleukin-1 beta (IL-1β) production and release from cortical microglia. The aim of this study was to determine whether, in addition, AT1 receptor blockade directly attenuates IL-1β-induced inflammatory responses in neuronal cultures.METHODS:SK-N-SH human neuroblasts and primary rat cortical neurons were pretreated with telmisartan followed by exposure to IL-1β. Gene expression was determined by reverse transcriptase (RT)-PCR, protein expression and kinase activation by western blotting, NADPH oxidase activity by the lucigenin method, prostaglandin E2 (PGE2) release by enzyme immunoassay, reactive oxygen species (ROS) generation by the dichlorodihydrofluorescein diacetate fluorescent probe assay, and peroxisome proliferator-activated receptor gamma (PPARγ) involvement was assessed with the antagonists GW9662 and T0070907, the agonist pioglitazone and the expression of PPARγ target genes ABCG1 and CD36.RESULTS:We found that SK-N-SH neuroblasts expressed AT1 but not AT2 receptor mRNA. Telmisartan reduced IL-1β-induced cyclooxygenase-2 (COX-2) expression and PGE2 release more potently than did candesartan and losartan. Telmisartan reduced the IL-1β-induced increase in IL-1R1 receptor and NADPH oxidase-4 (NOX-4) mRNA expression, NADPH oxidase activity, and ROS generation, and reduced hydrogen peroxide-induced COX-2 gene expression. Telmisartan did not modify IL-1β-induced ERK1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation or nuclear factor-κB activation but significantly decreased IL-1β-induced c-Jun N-terminal kinase (JNK) and c-Jun activation. The JNK inhibitor SP600125 decreased IL-1β-induced PGE2 release with a potency similar to that of telmisartan. The PPARγ agonist pioglitazone reduced IL-1β-induced inflammatory reaction, whereas telmisartan did not activate PPARγ, as shown by its failure to enhance the expression of the PPARγ target genes ABCG1 and CD36, and the inability of the PPARγ antagonists GW9662 and T0070907 to modify the effect of telmisartan on COX-2 induction. The effect of telmisartan on IL-1β-stimulated COX-2 and IL-1R1 mRNA expression and ROS production was replicated in primary rat cortical neurons.CONCLUSIONS:Telmisartan directly ameliorates IL-1β-induced neuronal inflammatory response by inhibition of oxidative stress and the JNK/c-Jun pathway. Our results support the hypothesis that AT1 receptor blockers are directly neuroprotective, and should be considered for the treatment of inflammatory conditions of the brain.

Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.

Multifunctional angiotensin II receptor blocker, telmisartan, prevents BBB breakdown and ameliorates cognitive impairment in type 2 diabetes mice with activation of PPAR-gamma

P1‐020: Multifunctional Angiotensin II Receptor Blocker, Telmisartan, Prevents BBB Breakdown and Ameliorates Cognitive Impairment in Type 2 Diabetes Mice with Activation of PPAR‐gamma

401 TELMISARTAN PREVENTS COGNITIVE DECLINE IN TYPE 2 DIABETIC MICE WITH IMPROVEMENT OF BLOOD-BRAIN BARRIER DISRUPTION PARTLY DUE TO PPAR-GAMMA ACTIVATION

Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.

P3‐271: Telmisartan, an Angiotensin II Receptor Blocker, Ameliorates Cognitive Impairment Induced by Amyloid Beta Injection Partly Due to Partial Agonistic Activation of PPAR‐gamma

Cognitive Deficit in Amyloid-Beta-Injected Mice Was Improved by Pretreatment with A Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-Gamma Activation

Telmisartan treatment ameliorates memory deficits in streptozotocin-induced diabetic mice via attenuating cerebral amyloidosis.

O4‐01‐04: Beneficial Effects of Angiotensin II Receptor Blockers on Metabolic Disorder‐induced Cognitive Impairment

A Novel Thiazolidinediones ATZD2 Rescues Memory Deficits in a Rat Model of Type 2 Diabetes Through Antioxidant and Anti-Inflammation

Telmisartan Protects Against Diabetic Vascular Complications in a Mouse Model of Obesity and Type 2 Diabetes, Partially Through Peroxisome Proliferator Activated Receptor-Γ-dependent Activity

P4‐206: Co‐treatment with Memantine and Compound 21, an Angiotensin II Type 2 Receptor Agonist, Prevents Cognitive Decline in Type 2 Diabetic Mice

Co-treatment with memantine and compound 21, an angiotensin II type 2 receptor agonist, prevents cognitive decline in type 2 diabetic mice

Possible Synergistic Effect of Direct Angiotensin II Type 2 Receptor Stimulation by Compound 21 with Memantine on Prevention of Cognitive Decline in Type 2 Diabetic Mice

Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells

Valsartan Improves the Cognition Impairment in Diabetic Mice and Underlying Mechanism

Telmisartan Directly Ameliorates the Neuronal Inflammatory Response to IL-1β Partly Through the JNK/c-Jun and NADPH Oxidase Pathways

Effects of an angiotensin Ⅱ type 1 receptor blocker telmisartan on secretory function of β-cell in db/db mice

Telmisartan protects against high glucose/high lipid‐induced apoptosis and insulin secretion by reducing the oxidative and ER stress

Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior

Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization